- Conditions
- Neoplasms
- Interventions
- letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 3
- States / cities
- Miami, Florida • Tampa, Florida • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 3,680
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lung Neoplasm Malignant
- Interventions
- Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, Pemetrexed, Sacituzumab tirumotecan, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Carboplatin, Pembrolizumab (adjuvant), Paclitaxel, Steroid mouthwash (dexamethasone or equivalent)
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 9
- States / cities
- Daphne, Alabama • Santa Barbara, California • Lone Tree, Colorado + 5 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- RAD001
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 23 Years to 76 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • New Orleans, Louisiana • Dallas, Texas + 1 more
- Conditions
- Stage IV Non-small Cell Lung Cancer, Cachexia
- Interventions
- Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients.
- Drug
- Lead sponsor
- Tu Dan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Malignant Airway Obstruction Secondary to Non-small Cell Lung Cancer
- Interventions
- Paclitaxel
- Drug
- Lead sponsor
- Mercator MedSystems, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Chapel Hill, North Carolina • Raleigh, North Carolina
- Conditions
- Carcinoma, Non-small Cell Lung
- Interventions
- REOLYSIN®, Carboplatin, Paclitaxel
- Biological · Drug
- Lead sponsor
- Oncolytics Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Columbus, Ohio
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
- Interventions
- LY4052031, Pembrolizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 22
- States / cities
- Duarte, California • La Jolla, California • Los Angeles, California + 15 more
- Conditions
- Non-small Cell Lung Cancer, NSCLC
- Interventions
- PembroRT
- Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Carcinoma, SMARCA4 Mutation, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Squamous Cell Carcinoma
- Interventions
- PRT7732
- Drug
- Lead sponsor
- Prelude Therapeutics Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 11
- States / cities
- San Francisco, California • Detroit, Michigan • New York, New York + 7 more
- Conditions
- Stage IV Non-Small Cell Lung Cancer
- Interventions
- Image-guided Radiation Therapy, Immunotherapy (physician's choice for standard of care immunotherapy)
- Radiation · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- KIF5B-RET-Positive Adenocarcinoma of the Lung
- Interventions
- Lenvatinib
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 8
- States / cities
- Duarte, California • La Jolla, California • Whittier, California + 5 more
- Conditions
- Lung Cancer
- Interventions
- docetaxel, gefitinib, laboratory biomarker analysis, radiation therapy
- Drug · Other · Radiation
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma
- Interventions
- CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab
- Drug
- Lead sponsor
- Corvus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Duarte, California • San Francisco, California + 18 more
- Conditions
- Advanced Solid Tumor
- Interventions
- DB-1310, Trastuzumab, Osimertinib, capecitabine
- Drug
- Lead sponsor
- DualityBio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 15
- States / cities
- Sacramento, California • Santa Monica, California • Coral Gables, Florida + 12 more
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Interventions
- RMC-9805, RMC-6236
- Drug
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 604 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 17
- States / cities
- Sacramento, California • New Haven, Connecticut • Sarasota, Florida + 12 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Atezolizumab
- Drug
- Lead sponsor
- Alliance Foundation Trials, LLC.
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • La Jolla, California • Chicago, Illinois + 10 more
- Conditions
- Non-small Cell Lung Cancer, Renal Cell Carcinoma
- Interventions
- Preoperative Ketorolac
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia
- Conditions
- Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer, NSCLC
- Interventions
- PRTH-101, Pembrolizumab
- Biological
- Lead sponsor
- Incendia Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 7 more
- Conditions
- Solid Tumor
- Interventions
- PF-07284892, lorlatinib, binimetinib, cetuximab, encorafenib
- Drug · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Detroit, Michigan + 6 more
- Conditions
- Cigarette Smoker, Current Smoker, Lung Adenocarcinoma, Squamous Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
- Interventions
- Best Practice, Biospecimen Collection, Laboratory Biomarker Analysis, Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration, Smoking Cessation Intervention
- Other · Procedure · Behavioral
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Colorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Interventions
- MM-151, MM-121, MM-141, trametinib
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Sandy Springs, Georgia • Chicago, Illinois + 2 more
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- GDC-0941, bevacizumab, carboplatin, cisplatin, paclitaxel, pemetrexed
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma
- Interventions
- Microwave Ablation
- Device
- Lead sponsor
- Ethicon, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 5
- States / cities
- Duarte, California • Rochester, Minnesota • New York, New York + 2 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Pharmacokinetic sampling - AZD9291, Rifampicin, AZD9291 tablet dosing, Pharmacokinetic sampling - rifampicin, Pharmacokinetic sampling - AZ5140 and AZ7550
- Procedure · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Detroit, Michigan